Endometriosis: A Global Strategic Business Report
GIA announces the release of a comprehensive global report on Endometriosis markets. The global market for endometriosis treatment is forecast to reach $1.31 billion by the year 2017. Major factors driving market growth include huge unmet need for novel and effective drugs in the market with improved safety profiles, increasing incidence rates of endometriosis due to environmental factors, rising awareness of the disease, and improved diagnosis. Drugs that are expected to drive future market growth include Abarelix, SERMs (Selective Estrogen Receptor Modulators), Extracellular Matrix Modulators, Terbutaline, and RU-486.
San Jose, CA (Vocus/PRWEB) April 04, 2011
Endometriosis is the most common health problem among women.
As per the estimates of World Endometriosis Research Foundation, an estimated 170 million women suffer from endometriosis globally. Endometriosis-related healthcare costs and productivity losses exceed US$4,000 per patient annually. Annual direct and indirect endometriosis-related costs are estimated to cross US$20 to US$25 billion in the US over the coming years. The disease affects reproductive age women more compared to post-menopausal women. Endometriosis affects more than 90 million women of reproductive age globally. The disease represents one of the major causes of female infertility and constitutes for about 30% of infertility cases in women. More than 7.8 million women in the US suffer from endometriosis-related symptoms, which include chronic pelvic pain, dysmenorrhea, and infertility.
Gonadotropin-Releasing Hormone GnRH agonists, Progestins, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and contraceptives are the major therapeutic options available for the treatment of endometriosis. The present drugs are characterized by safety and efficacy concerns. Huge unmet medical need exists for novel medication with improved safety profile and minimal side effects. Lupron Depot from Abbott Laboratories, Depo-Provera and Synarel from Pfizer, are the major drugs approved for the treatment of endometriosis. Abbott's Lupron (Leuprolide) represents one of the leading drugs for the treatment of endometriosis.
The global endometriosis market is led by the US, as stated by a new market research report on Endometriosis. Europe represents the next largest region, while growth is expected to emanate mainly from the ‘Rest of the world’ market, which is expected to depict a compounded annualized growth of more than 6.0% during 2009-2017. The future looks promising for endometriosis, with increasing efforts being made in research, and novel treatment emerging in the field of surgical as well as pharmaceutical treatment. In addition, myths are being dispelled regarding the disease, and alternative methods are being readily accepted. Non-invasive diagnostics, including next-generation MRIs, are forecast to become major tools for the diagnosis of endometriosis, although laparoscopy, an invasive surgery, still remains the gold standard for performing disease diagnosis. Genetic and biomolecular diagnostic tests are also being trailed.
Drugs that are expected to drive future market growth include Abarelix, SERMs (Selective Estrogen Receptor Modulators), Extracellular Matrix Modulators, Terbutaline, and RU-486. Abarelix, for instance, is a GnRH antagonist, presently undergoing clinical trials in the US for its use in endometriosis. The emergence of certain other promising innovative drugs, including Repros Therapeutics’ Proellex, Neurocrine’s Elagolix, and Bayer HealthCare Pharmaceuticals’ Visanne (Dienogest) is forecast to have a robust impact on the endometriosis market in future. Elagolix is the first oral non-peptide gonadotropin-releasing hormone (GnRH) antagonist. Meanwhile, Proellex acts by selectively blocking the activity of progesterone, and allows the secretions of tonic hormone by alleviating the negative side effects of GnRHa. Besides pipeline drugs, Angiogenesis therapy is forecast to be one of the key potential treatment options for endometriosis, whether used alone or as an adjunct therapy. Angiogenesis theory holds that endometriosis lesions could be destroyed by cutting off the blood supply.
Major players profiled in the report include Abbott Laboratories, AEterna Zentaris Inc., AstraZeneca Plc., Bayer HealthCare Pharmaceuticals Inc., Eli Lilly and Company, Meditrina Pharmaceuticals Inc., Neurocrine Biosciences Inc., Paladin Labs Inc., Pfizer Inc., Repros Therapeutics Inc., among others.
The research report titled “Endometriosis: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of endometriosis, current market trends, key growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Endometriosis treatment for the years 2009 through 2017 for the following geographic markets - US, Canada, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Endometriosis_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
E-mail: press(at)StrategyR(dot)com
Web Site:
http://www.StrategyR.com/
